A comprehensive GxP compliance playbook that maps 21 CFR Part 11, EU GMP Annex 11, GAMP 5 and ALCOA+ requirements into a practical validation sequence for pharmaceutical digital systems. Designed for QA, IT/OT and engineering teams preparing for system implementation.
Regulatory requirements mapping
Each GxP digital system must be mapped against applicable regulations: FDA 21 CFR Part 11 for US market or FDA-inspected facilities, EU GMP Annex 11 for EU market or EMA-audited sites, GAMP 5 for validation methodology, and WHO-GMP for Vietnam domestic market. The mapping drives the validation scope, evidence type and inspection readiness level.
Validation sequence and evidence chain
The validation sequence: Validation Plan → URS (functional requirements + GxP risk classification) → Supplier Assessment → Design/Configuration Specification → IQ (installation qualification) → OQ (operational qualification) → PQ (performance qualification in production conditions) → Validation Summary Report. Ongoing: Change Control → Periodic Review → Revalidation trigger assessment.
Vietnam-specific compliance context
Vietnamese pharmaceutical manufacturers pursuing EU-GMP certification (required for export to regulated markets) must demonstrate computerised system validation that satisfies both Vietnam's Ministry of Health GMP guidelines and EU GMP Annex 11. The gap between domestic requirements and export-market standards is a major driver for MES, QMS and LIMS implementation projects.
How to use this page
Use this GxP Compliance Validation Playbook page as a planning checkpoint before vendor selection, architecture review, validation scoping or implementation sequencing. The strongest next step is to compare the guidance with your current SOPs, system inventory, batch records, data flows and QA review routines so the discussion starts from evidence instead of assumptions.
Evidence to prepare
For GxP Compliance Validation Playbook, prepare the records, owners, risks and decision criteria linked to regulatory requirements mapping, validation sequence and evidence chain, vietnam-specific compliance context. Useful evidence includes current process maps, interface lists, audit trail expectations, exception workflows, data retention rules and the business reason for changing the current operating model.
Frequently asked questions
What is GxP and which pharmaceutical systems require GxP validation?
GxP refers to a collection of Good Practice guidelines governing pharmaceutical manufacturing (GMP), clinical trials (GCP), laboratory operations (GLP) and distribution (GDP). For digital manufacturing systems, GxP validation is required for any system that: creates or manages GxP records (batch records, LIMS results, deviations), controls or monitors GMP processes, manages electronic signatures for product release, or supports QA review and batch disposition decisions. This includes MES, LIMS, QMS, ERP batch modules, data historians, SCADA systems and environmental monitoring.
How long does a GxP system validation project typically take in Vietnam?
For a GAMP 5 Category 4 system (commercial MES, LIMS or QMS), a complete validation project in a Vietnamese pharma plant typically takes 4–8 months: 2–4 weeks for URS and supplier assessment, 4–6 weeks for configuration specification, 8–12 weeks for IQ/OQ protocol execution, and 4–6 weeks for PQ under production conditions. Regulatory submissions and management approval add time. Projects at plants pursuing EU-GMP certification typically require external GMP consultant review of validation deliverables.
Can a system that was validated under an older standard be accepted under GAMP 5 Second Edition?
Yes. GAMP 5 Second Edition is backward-compatible — it provides a risk-based framework, not a retroactive testing requirement. A previously validated system under GAMP 5 First Edition remains valid as long as change control has been maintained. At the next major upgrade or periodic review, the validation approach should be updated to reflect GAMP 5 Second Edition principles, particularly the emphasis on critical thinking and CSA alignment.